TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37918921

Group type: EXPERIMENTAL
Intervention: Geriatric Fracture Centers (GFCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care centres
Number of subjects: 0
Study: 37918933

Group type: EXPERIMENTAL
Intervention: PERSARC (personalised risk assessment tool)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 120
Study: 37918956

Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy followed by inguinofemoral lymph node dissection in group 1 (tumors ≥4 cm)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy followed by inguinofemoral lymph node dissection in group 2 (multifocal tumors)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Node-positive patients (32% had micrometastasis or isolated tumor cells only)
Number of subjects: 64
Study: 37919179

Group type: EXPERIMENTAL
Intervention: Buzzy®
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: DistrACTION® Cards
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study: 37919269

Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy with oleclumab (arm A)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Chemo-immunotherapy without oleclumab (arm B)
Number of subjects: 127
Study: 37919313

Group type: EXPERIMENTAL
Intervention: eltrombopag
Number of subjects: 20
Study: 37919438

Group type: EXPERIMENTAL
Intervention: autologous bone marrow aspirate concentrate (n=120)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: umbilical cord tissue-derived mesenchymal stromal cells (n=120)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: stromal vascular fraction (n=120)
Number of subjects: 480

Group type: COMPARATOR
Intervention: corticosteroid injection (CSI) (n=40)
Number of subjects: 480
Study: 37919448

Group type: EXPERIMENTAL
Intervention: TPF chemotherapy followed by surgery
Number of subjects: 47
Study: 37919456

Group type: EXPERIMENTAL
Intervention: TTV DNA load < 4.05 log10 copies/ml at ICANS onset
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Falling or stable TTV DNA load between lymphodepletion and CAR-T infusion
Number of subjects: 79
Study: 37919483

Group type: COMPARATOR
Intervention: ASC42 5-200 mg (SAD)
Number of subjects: 65

Group type: COMPARATOR
Intervention: ASC42 5-50 mg (MAD) once-daily for 14 days
Number of subjects: 65

Group type: COMPARATOR
Intervention: ASC42 15 mg with a high-fat meal
Number of subjects: 65

Group type: COMPARATOR
Intervention: ASC42 (various doses)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 37919512

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 67
Study: 37919617

Group type: EXPERIMENTAL
Intervention: Diazoxide choline extended-release tablet (DCCR)
Number of subjects: 125
Study: 37919629

Group type: EXPERIMENTAL
Intervention: Postoperative portal flow pulsatility
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Postoperative splenic pulsatility indices
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Portal pulsatility index
Number of subjects: 389
Study: 37919630

Group type: EXPERIMENTAL
Intervention: Nova StatStrip glucometer
Number of subjects: 135

Group type: COMPARATOR
Intervention: High-dose insulin therapy (HNC)
Number of subjects: 135
Study: 37919668

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg or 840 mg once daily with standard doses of everolimus for RCC
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg or 840 mg once daily with standard doses of docetaxel for GC
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg or 840 mg once daily with standard doses of cetuximab for CRC
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg or 840 mg once daily
Number of subjects: 135
Study: 37919676

Group type: EXPERIMENTAL
Intervention: NP-led huddles
Number of subjects: 42
Study: 37919695

Group type: EXPERIMENTAL
Intervention: Early tracheal extubation
Number of subjects: 213

Group type: COMPARATOR
Intervention: Prolonged mechanical ventilation
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Red blood cell infusion
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Postreperfusion syndrome
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Reoperations
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: ICU readmissions
Number of subjects: 213
Study: 37919697

Group type: EXPERIMENTAL
Intervention: Monthly Nuvaring® (vaginal ring)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Daily combined oral contraceptive (daily pills)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bi-monthly injectable contraceptive (injectable)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Vaginal ring
Number of subjects: 33

Group type: COMPARATOR
Intervention: Daily pills
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Injectable
Number of subjects: 33
Study: 37919705

Group type: EXPERIMENTAL
Intervention: Person-centred eHealth intervention
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Phone calls with health care professionals
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of participants' experiences
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 102
Study: 37919742

Group type: EXPERIMENTAL
Intervention: Progressive reduction of sodium intake (PR) in 24 facilities
Number of subjects: 1612

Group type: COMPARATOR
Intervention: No reduction of sodium intake (NR) in 24 facilities
Number of subjects: 1612

Group type: EXPERIMENTAL
Intervention: Progressive reduction of sodium intake (PR)
Number of subjects: 1612

Group type: COMPARATOR
Intervention: No reduction of sodium intake (NR)
Number of subjects: 1612
Study: 37919761

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 163

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 163

Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 163
Study: 37919780

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 4932

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4932
Study: 37919791

Group type: EXPERIMENTAL
Intervention: NT-proBNP T3 level
Number of subjects: 5093

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 5093
Study: 37919815

Group type: EXPERIMENTAL
Intervention: EaveTubes (ETs) + Long-Lasting Insecticidal Nets (LLINs)
Number of subjects: 1870

Group type: COMPARATOR
Intervention: Long-Lasting Insecticidal Nets (LLINs) only
Number of subjects: 1870

Group type: EXPERIMENTAL
Intervention: EaveTubes (ETs)
Number of subjects: 1870
Study: 37919816

Group type: EXPERIMENTAL
Intervention: Zidovudine/lamivudine/boosted lopinavir following 10 to 18 days of nutritional rehabilitation
Number of subjects: 52
Study: 37919940

Group type: EXPERIMENTAL
Intervention: Ranibizumab intravitreal therapy
Number of subjects: 46
Study: 37920150

Group type: EXPERIMENTAL
Intervention: Covid-19 convalescent plasma (4 units, 200-220 mL/unit, 2 units/day over two consecutive days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Covid-19 convalescent plasma
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Covid-19 convalescent plasma in immunocompromised patients
Number of subjects: 120
Study: 37920192

Group type: EXPERIMENTAL
Intervention: Intensive therapy group (upload glucose data weekly for 4 months, receive support from diabetes care team)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (standard diabetes support, same number of clinical visits as intensive group)
Number of subjects: 120
Study: 37920410

Group type: EXPERIMENTAL
Intervention: 0.15% Azelastine hydrochloride (AZE), two sprays per nostril twice daily for 4 weeks
Number of subjects: 581

Group type: COMPARATOR
Intervention: 0.10% Azelastine hydrochloride (AZE), dosage not specified
Number of subjects: 581

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 581
Study: 37920522

Group type: EXPERIMENTAL
Intervention: Algorithm Guided Treatment (AGT)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 581
Study: 37920607

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study: 37920733

Group type: EXPERIMENTAL
Intervention: Unified Protocol for the transdiagnostic treatment of EDs
Number of subjects: 60
Study: 37920779

Group type: EXPERIMENTAL
Intervention: MuST AKT intervention (standard care plus the MuST AKT intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study: 37920793

Group type: EXPERIMENTAL
Intervention: Mediterranean diet during pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular diet during pregnancy
Number of subjects: 0
Study: 37920802

Group type: EXPERIMENTAL
Intervention: Wheelchair propulsion fatigue protocol (15-min duration, three 4-min rounds with 90 s rest)
Number of subjects: 50
Study: 37920833

Group type: EXPERIMENTAL
Intervention: Betahistine 48 mg with selegiline (5 mg/d for 7 days)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Betahistine 48 mg alone
Number of subjects: 15
Study: 37920858

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment on days 1 and 2 in addition to standard postoperative pain management
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard postoperative pain management
Number of subjects: 80
Study: 37920859

Group type: EXPERIMENTAL
Intervention: Press-tack needle acupuncture
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 37920915

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37920921

Group type: EXPERIMENTAL
Intervention: Cobicistat + gemcitabine + nab-paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine + nab-paclitaxel
Number of subjects: 0
Study: 37920963

Group type: EXPERIMENTAL
Intervention: Cannabidiol 150-300 mg/day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cannabidiol 300 mg/day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cannabidiol
Number of subjects: 35
Study: 37921006

Group type: EXPERIMENTAL
Intervention: ADT ON (continuation of antiarrhythmic drug therapy)
Number of subjects: 200

Group type: COMPARATOR
Intervention: ADT OFF (discontinuation of antiarrhythmic drug therapy)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups (ADT ON and ADT OFF)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ADT ON and ADT OFF
Number of subjects: 200
Study: 37921353

Group type: EXPERIMENTAL
Intervention: Accelerated continuous theta burst stimulation (cTBS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 40
Study: 37921410

Group type: EXPERIMENTAL
Intervention: PVRV-NG2 (three different doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HDCV (Imovax rabies®)
Number of subjects: 0
Study: 37921461

Group type: EXPERIMENTAL
Intervention: Sparsentan
Number of subjects: 371

Group type: COMPARATOR
Intervention: Irbesartan (active control)
Number of subjects: 371
Study: 37921522

Group type: EXPERIMENTAL
Intervention: Perfluorohexyloctane (PFHO) ophthalmic drop, 1 drop 4 times daily for 52 weeks
Number of subjects: 208

Group type: COMPARATOR
Intervention: Saline (control group in GOBI study)
Number of subjects: 208
Study: 37921599

Group type: EXPERIMENTAL
Intervention: Laparoscopic Visceral-Peritoneal Debulking (L-VPD)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Visceral-Peritoneal Debulking (VPD)
Number of subjects: 208
Study: 37921644

Group type: EXPERIMENTAL
Intervention: Preoperative nutritional status assessed by GNRI (Geriatric Nutritional Risk Index)
Number of subjects: 2775

Group type: EXPERIMENTAL
Intervention: Preoperative nutritional status assessed by PNI (Prognostic Nutritional Index)
Number of subjects: 2775

Group type: EXPERIMENTAL
Intervention: Preoperative nutritional status assessed by CONUT (Controlling Nutritional Status)
Number of subjects: 2775

Group type: EXPERIMENTAL
Intervention: Postoperative AKI incidence
Number of subjects: 2775

Group type: EXPERIMENTAL
Intervention: Nutritional indices in AKI prediction models
Number of subjects: 2775
Study: 37921755

Group type: EXPERIMENTAL
Intervention: Giredestrant (10, 30, 90, or 250 mg)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Giredestrant (100 mg) + Palbociclib (125 mg) ± LHRH agonist
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Giredestrant (single-agent) ± LHRH agonist
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Giredestrant (100 mg)
Number of subjects: 175
Study: 37921769

Group type: EXPERIMENTAL
Intervention: Extrauterine placental perfusion (EPP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delayed cord clamping (DCC)
Number of subjects: 60
Study: 37921846

Group type: EXPERIMENTAL
Intervention: Resilience Enhancement Skills Training (REST)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Standard of care (VCT-based problem-solving individual therapy)
Number of subjects: 166
Study: 37922035

Group type: EXPERIMENTAL
Intervention: P140 peptides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antioxidant drug apocynin
Number of subjects: 0
Study: 37922055

Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE) with ethylene vinyl alcohol copolymer (EVOH)
Number of subjects: 10
Study: 37922156

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (administrative support, educational resources, storytelling initiative, performance reports)
Number of subjects: 20375

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20375
Study: 37922279

Group type: EXPERIMENTAL
Intervention: Music intervention combined with progressive muscle relaxation (self-practice daily for three weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard care (health assessment, regular health advice, and nutrition consultation)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Music intervention combined with progressive muscle relaxation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 24
Study: 37922432

Group type: EXPERIMENTAL
Intervention: Early trends of OS prognostic biomarkers (ROPRO and DeepROPRO)
Number of subjects: 19920

Group type: EXPERIMENTAL
Intervention: Early OS within the joint model (JM) framework
Number of subjects: 19920
Study: 37922438

Group type: EXPERIMENTAL
Intervention: Single dose of PSMA-targeting alpha emitter via antibody delivery
Number of subjects: 32
Study: 37922442

Group type: EXPERIMENTAL
Intervention: Adjuvant Hyperthermic Intraperitoneal Chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37922692

Group type: EXPERIMENTAL
Intervention: Targeted therapy/cancer immunotherapy
Number of subjects: 464

Group type: COMPARATOR
Intervention: Platinum-based chemotherapy
Number of subjects: 464
Study: 37922694

Group type: EXPERIMENTAL
Intervention: Higher dietary protein intake (total, animal, plant)
Number of subjects: 2709
Study: 37922883

Group type: EXPERIMENTAL
Intervention: Polygenic risk scores (PRSs) implementation in primary care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced recruitment strategies for underrepresented race and ethnicity groups
Number of subjects: 0
Study: 37922910

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 immunotherapy combined with standard-of-care chemo-hormonal therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care chemo-hormonal therapy
Number of subjects: 0
Study: 37922930

Group type: EXPERIMENTAL
Intervention: Single dose of lutetium-177
Number of subjects: 43
Study: 37922989

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Anti-CD20 radioimmunotherapy (RIT)
Number of subjects: 159
Study: 37923161

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg/day, N = 45)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (N = 42)
Number of subjects: 87
Study: 37923301

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous Spontaneous Breathing (CSB)
Number of subjects: 40
Study: 37923345

Group type: EXPERIMENTAL
Intervention: Fortified balanced energy-protein (BEP) supplement during pregnancy and lactation
Number of subjects: 100000

Group type: COMPARATOR
Intervention: No supplementation (control)
Number of subjects: 100000
Study: 37923529

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37923615

Group type: EXPERIMENTAL
Intervention: Maternal-targeted training on nonpharmacological pain management
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nonpharmacological methods (control group)
Number of subjects: 64
Study: 37923987

Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (SCRT) followed by four cycles of FOLFOX (oxaliplatin, 5-fluorouracil, and folinic acid) as a neoadjuvant treatment.
Number of subjects: 364

Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT) (45-50.4 Gy in 25-28 fractions, 5 times a week) concurrently with capecitabine or 5-fluorouracil.
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: SCRT followed by FOLFOX chemotherapy.
Number of subjects: 364

Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT).
Number of subjects: 364
Study: 37924021

Group type: EXPERIMENTAL
Intervention: Preformed zirconia crowns (ZCs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Stainless-steel crowns (SSCs)
Number of subjects: 20
Study: 37924063

Group type: EXPERIMENTAL
Intervention: Introvision training (experimental group)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Introvision training (experimental group) and waiting list group (pooled data)
Number of subjects: 51
Study: 37924084

Group type: EXPERIMENTAL
Intervention: Segmental LPS challenge
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhalation LPS challenge
Number of subjects: 10
Study: 37924083

Group type: COMPARATOR
Intervention: TECH (Fitbit, step goals, app, feedback)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: TECH + Gamification
Number of subjects: 116

Group type: COMPARATOR
Intervention: TECH (Fitbit)
Number of subjects: 116
Study: 37924101

Group type: EXPERIMENTAL
Intervention: 4 teleconsultations of 45 min with a psychologist
Number of subjects: 932
Study: 37924154

Group type: EXPERIMENTAL
Intervention: PSMA PET/CT imaging
Number of subjects: 117
Study: 37924247

Group type: EXPERIMENTAL
Intervention: Online exposure and response prevention therapy for 10 weeks
Number of subjects: 224

Group type: COMPARATOR
Intervention: Online psychoeducation for 10 weeks
Number of subjects: 224
Study: 37924356

Group type: EXPERIMENTAL
Intervention: Core stability training with Rocabado exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rocabado exercises (Control)
Number of subjects: 0
Study: 37924481

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treatment
Number of subjects: 619
Study: 37924483

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL)
Number of subjects: 1862
Study: 37924574

Group type: EXPERIMENTAL
Intervention: Clinical algorithms for dysphagia management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emerging therapeutic options such as neurostimulation
Number of subjects: 0
Study: 37924624

Group type: EXPERIMENTAL
Intervention: Starch- and sucrose-reduced diet for 4 weeks
Number of subjects: 2
Study: 37924716

Group type: EXPERIMENTAL
Intervention: Secondary auricular reconstructions based on the Nagata method
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Projection surgeries only (Cases 5 and 6)
Number of subjects: 7
Study: 37924833

Group type: EXPERIMENTAL
Intervention: Subcutaneous TV-46000 once monthly
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Subcutaneous TV-46000 once every 2 months
Number of subjects: 544

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Subcutaneous TV-46000 (both groups)
Number of subjects: 544
Study: 37924841

Group type: EXPERIMENTAL
Intervention: VRE colonisation present in 49 (20%) participants; environmental surfaces contaminated in 36 (73%) of these patients.
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Antibiotic exposure within the past 30 days (high-risk antibiotics p=0.011 and low-risk antibiotics p=0.0004)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Antibiotic exposure (adjusted odds ratio 2.75 [95% CI 1.22-6.16]) and male sex (2.75 [1.24-6.08])
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Physical dependence (0.91 [0.83-0.99])
Number of subjects: 245
Study: 37924856

Group type: EXPERIMENTAL
Intervention: MNS 10 mg
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 37924939

Group type: EXPERIMENTAL
Intervention: WaveOne Gold Glider (WOGG)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: ProGlider (PG)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study: 37925053

Group type: EXPERIMENTAL
Intervention: Purse-string double-layer closure (Turan technique) for uterine incision repair
Number of subjects: 0
Study: 37925316

Group type: EXPERIMENTAL
Intervention: LVRNA009 (25, 50, and 100 μg)
Number of subjects: 72
Study: 37925363

Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir (LDV/SOF) 45/200 mg once-daily orally for 12 weeks (chemotherapy treatment group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no malignancy)
Number of subjects: 22
Study: 37925394

Group type: EXPERIMENTAL
Intervention: Group psychoeducational program
Number of subjects: 332
Study: 37925402

Group type: EXPERIMENTAL
Intervention: Introduction of London's Ultra Low Emission Zone (ULEZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Luton (comparator site)
Number of subjects: 0
Study: 37925450

Group type: EXPERIMENTAL
Intervention: Formal peer PrEP referral + HIVST delivery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Informal peer PrEP referral
Number of subjects: 80
Study: 37925471

Group type: EXPERIMENTAL
Intervention: Tenapanor 5 mg twice daily (up to 30 mg twice daily)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Tenapanor 5 mg twice daily
Number of subjects: 212
Study: 37925512

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) guided surfactant therapy
Number of subjects: 668

Group type: COMPARATOR
Intervention: Standard surfactant therapy
Number of subjects: 668
Study: 37925557

Group type: EXPERIMENTAL
Intervention: Theta burst stimulation (TBS) treatment, 10 daily sessions in clinical trial one
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Theta burst stimulation (TBS) treatment, 20 daily sessions in clinical trial two
Number of subjects: 30